Skip to main content

Advertisement

Table 3 Frequency of adverse events and nontreatment-emergent adverse events by preferred term

From: Relative bioavailability of diazoxide, manufactured at two different international locations, in healthy participants under fasting conditions: an open-label, two-stage, adaptive, sequential two-period crossover study

  AEs, n
Preferred Term Test Treatment Reference Treatment
Bacterial test positive 1 1
Dry throat 1  
Hyperglycemia 1  
Hypoglycemia 1  
Somnolencea 1  
Urine leukocyte esterase positive 1  
Vomiting 1  
White blood cells urine positive 1  
Dizziness   1
Headache   3
Influenza-like illness   1
Nausea   1
Nitrite urine present   1
Oropharyngeal pain   1
Sinus congestion   1
Urine leukocyte esterase positive   1
White blood cells urine positive   1
Total 8 12
  1. aNTEAE
  2. AEs adverse events, NTEAE nontreatment emergent adverse event
  3. Test, PROGLICEM® 100 mg hard capsules, Batch No.: 3107A (Merck Sharp & Dohme Corp, USA); reference, PROGLYCEM® 100 mg capsules, Lot No.: 120118 (Merck Canada Inc., Canada)